The stock is listed on the Nasdaq Global Market

Davis Polk advised the sales agent in connection with a $50 million SEC-registered at-the-market offering by NeuroPace, Inc. of its common stock. NeuroPace’s common stock is listed on the Nasdaq Global Market under the symbol “NPCE.”

Based in Mountain View, California, NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Sarah Catherine Chouinard and Michelle Zhang. Partner David R. Bauer and associate Jordan Khorshad provided intellectual property advice. Counsel Leon E. Salkin provided Investment Company Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.